Alkermes Plc Hits New 52-Week High of $44.91, Up 83% Yearly

Alkermes Plc has reached a significant milestone by hitting a new 52-week high of USD 44.91 on June 9, 2026. This achievement reflects the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it has demonstrated a remarkable one-year performance of 83.09%, significantly outpacing the S&P 500's 22.99% during the same period. With a market capitalization of USD 5,008 million, Alkermes is classified as a small-cap company. The stock's price-to-earnings (P/E) ratio stands at 21.00, indicating a competitive valuation within its industry. Additionally, the company maintains a return on equity of 13.28%, showcasing its ability to generate profits from shareholders' equity. Despite a debt-to-equity ratio of -0.72, which suggests a unique capital structure, Alkermes has not offered dividends, as indicated by a yield of 0.00%. The stock's previous 52-week low was recorded at USD 25.17, highlighting the significant upward movement in its price. This new high marks a pivotal moment for Alkermes Plc as it continues to navigate the dynamic landscape of the pharmaceutical industry.